IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome.
Lanny J
LJ
Rosenwasser
Marc E
ME
Rothenberg
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D015267:Churg-Strauss Syndrome / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D004802:Eosinophilia / Q000517:prevention & control; D006801:Humans; D007167:Immunotherapy; D015848:Interleukin-5 / Q000037:antagonists & inhibitors*; D009298:Nasal Polyps / Q000517:prevention & control; D053649:Receptors, Interleukin-5 / Q000276:immunology; D055502:Secondary Prevention; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; D053649:Receptors, Interleukin-5; C515492:reslizumab; C434107:mepolizumab